ANNEX II, Regulation (EU) 2020/1069

In forcesince 19 Jun 2020

[The last year of the availability period or of a possible disbursement of the Pandemic Crisis Support (whichever is earlier) is also the last year of the reporting, unless the Member State has not yet used all the funds drawn.] [Items and sub-items, as necessary, accompanied with the relevant explanations to allow the Commission to perform a meaningful assessment.] [This can include, inter alia, spending on hospitals; cure and rehabilitative care, ambulatory cure and rehabilitative care, diagnostics, pharmaceuticals, preventive care, health administrations, and health related long-term care.]

Year 2020 | Year 2021 |

In EUR million

Time series of actual data ending at quarter of the respective report to be submitted

Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4

Healthcare, cure and prevention costs directly related to the COVID-19 pandemic | | | | | | | |

[Item] | | | | | | | |

[Further items as necessary] | | | | | | | |

Part of overall public healthcare spending estimated to be directly or indirectly attributed to addressing the impact of COVID-19 on the healthcare system | | | | | | | |

[Item] | | | | | | | |

[Further items as necessary] | | | | | | | |

Other indirect costs related to healthcare, cure and prevention due to the COVID-19 crisis | | | | | | | |

[Item] | | | | | | | |

[Further items as necessary] | | | | | | | |